You just read:

BioMarin Announces New England Journal of Medicine Publishes Vosoritide Phase 2 Study Showing Sustained Annualized Growth Up to 42 Months in Children with Achondroplasia

News provided by

BioMarin Pharmaceutical Inc.

Jun 18, 2019, 08:31 ET